Pasco, Paul Matthew D.
Jamora, Roland Dominic G. http://orcid.org/0000-0001-5317-7369
Rosales, Raymond L.
Diesta, Cid Czarina E.
Ng, Arlene R.
Teleg, Rosalia A.
Go, Criscely L.
Lee, Lillian
Fernandez, Hubert H.
Article History
Received: 1 January 2017
Revised: 24 June 2017
Accepted: 27 June 2017
First Online: 25 July 2017
Competing interests
: Dr. Rosales has consultancies for Ipsen, Pfizer, Abbott, Menarini, Otsuka, Boehringer; on the advisory boards for Ipsen and Pfizer; has received speakership fees and travel grants from Ipsen, Pfizer, Abbott, Menarini, Otsuka, Boehringer; and is overall lead investigator for a spasticity clinical trial. Dr. Jamora is on the advisory boards of the Philippine offices of Lundbeck and Torrent and has received honoraria from the Philippine offices of Abbott, Allergan, Medichem, Natrapharm, Sun Pharma and the international offices of Novartis, UCB and Lundbeck. He has received research grants from Collaborative Center for XDP (CCXDP). He has ongoing clinical trials for Allergan and Ipsen as primary investigator in Manila. He has no owner interest in any pharmaceutical company. Dr. Fernandez has received research support from Abbvie, Acadia, Auspex/Teva, Biotie Therapeutics, Civitas, Kyowa/Prostrakan, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Rhythm, Synosia, but has no owner interest in any pharmaceutical company. He has received honoraria from Prime Education Inc, Ohio State University, International Parkinson and Movement Disorders Society, Carling Communications, Medscape as a speaker in CME events. Dr. Fernandez has received honoraria from Biogen, GE Health Care, Lundbeck, Merz Pharmaceuticals and Pfizer Pharmaceuticals, as a consultant. He has received royalty payments from Demos Publishing for serving as a book author/editor. The Cleveland Clinic has contracts with Abbvie, Merz Pharmaceuticals, and Auspex/Teva for Dr. Fernandez’ role as a member of the Global Steering Committee for LCIG studies and as a consultant or speaker. He is the Head Principal Investigator for the Xeomin Registry Study; and Co-Principal Investigator in SD-809 Tardive Dyskinesia global studies. Dr. Fernandez also serves as the Chair of the Publication Committee for Xeomin Studies (Merz Pharmaceuticals); a member of the Publication Committee for Dysport studies (Ipsen Pharmaceuticals) but he does not receive any personal compensation for these roles. Dr. Fernandez has received a stipend from International Parkinson and Movement Disorders Society for serving as Medical Editor of the MDS Web Site.The remaining authors declare that they have no competing financial interests.